Sorafenib (Nexavar)
Sponsors
Clavis Pharma, Veeda Oncology, Italian Trial in Medical Oncology, Sponsor GmbH, Leiden University Medical Center
Conditions
Breast CancerMalignant MelanomaNon-Small Cell Lung CancerProstate CancerRecurrent or Progressive Low-grade GliomaRecurrent or Progressive Optic Pathway Gliomas (OPG)Renal Cell CarcinomaThyroid Cancer
Phase 2
Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma
CompletedNCT00498836
Start: 2007-03-31End: 2008-10-31Updated: 2013-09-12
A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer
TerminatedNCT00607438
Start: 2007-09-30End: 2009-05-31Updated: 2012-05-11
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer
CompletedNCT00619996
Start: 2007-03-31End: 2009-01-31Target: 43Updated: 2009-02-26
Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma
CompletedNCT00887107
Start: 2007-10-31Updated: 2009-04-23
Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
CompletedNCT00922584
Start: 2008-12-31End: 2012-04-30Updated: 2013-08-21
Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas
TerminatedNCT01338857
Start: 2011-04-30End: 2013-03-31Updated: 2017-02-17